To the full analysis
Buyback calculator for Valerio Therapeutics
Valerio Therapeutics stock: key metrics
ALVIO.PAValerio Therapeutics had an operating margin of −21.4% and a return on invested capital (ROIC) of −6.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 68.9% | −2,966.0% | −2,863.1% |
| 2007 | 98.5% | −554.3% | −517.1% |
| 2008 | 96.2% | −283.7% | −261.4% |
| 2009 | 94.7% | −205.4% | −204.1% |
| 2010 | 96.2% | 11.5% | 12.5% |
| 2011 | −195.6% | −462.4% | −452.6% |
| 2012 | 90.7% | −285.9% | −286.7% |
| 2013 | 82.0% | −1,052.5% | −1,044.5% |
| 2014 | 98.9% | −2.8% | −34.9% |
| 2015 | 90.3% | −636.9% | −557.4% |
| 2016 | 85.2% | −523.7% | −512.5% |
| 2017 | 93.3% | −201.9% | −621.5% |
| 2018 | 96.5% | −255.3% | −153.4% |
| 2019 | 91.8% | −228.4% | −786.6% |
| 2020 | 80.5% | −503.3% | 61.3% |
| 2021 | 90.9% | −180.4% | −146.2% |
| 2022 | 64.4% | −1,186.1% | −1,355.6% |
| 2023 | 70.4% | −1,127.1% | −1,130.2% |
| 2024 | 71.4% | −919.6% | −1,334.7% |
| 2025 | 67.1% | −21.4% | −190.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −69.4% | −54.4% | −58.0% |
| 2007 | −39.3% | −45.9% | −28.7% |
| 2008 | −78.5% | −48.4% | −50.4% |
| 2009 | −100.0% | −57.2% | −72.1% |
| 2010 | 14.9% | 14.7% | 10.7% |
| 2011 | −63.8% | −49.3% | −42.9% |
| 2012 | −98.3% | −42.1% | −52.2% |
| 2013 | −100.0% | −90.2% | −86.3% |
| 2014 | −6.3% | −1.6% | −5.1% |
| 2015 | −18.9% | −25.9% | −15.0% |
| 2016 | −24.1% | −27.3% | −18.1% |
| 2017 | −100.0% | −30.1% | −75.7% |
| 2018 | −20.7% | −32.1% | −14.9% |
| 2019 | −100.0% | −25.3% | −89.6% |
| 2020 | 3.8% | −21.9% | 2.3% |
| 2021 | −18.0% | −25.3% | −11.2% |
| 2022 | −87.8% | −63.2% | −45.4% |
| 2023 | −100.0% | −92.2% | −57.7% |
| 2024 | 200.0% | −80.2% | −100.0% |
| 2025 | −100.0% | −6.9% | −32.2% |
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2024)
- Valuation signal Overvalued since 10 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.